Pregnancy, breastfeeding, and peptides: what the absence of data means

Pregnancy and lactation safety data for a drug comes almost entirely from a combination of animal reproduction studies, human pregnancy registries that track outcomes in people who happen to be exposed, and, occasionally, controlled trials in narrow, medically necessary circumstances. For research peptides sold outside the approved drug system, essentially none of that infrastructure exists. There are no pregnancy registries, no formal reproductive toxicology filings, and no regulatory requirement to study these compounds in pregnant or breastfeeding people, because they are not approved drugs in the first place. That is a meaningfully different situation from a drug with limited or conflicting pregnancy data; it is closer to no data at all.

The FDA's Pregnancy and Lactation Labeling Rule (PLLR), finalized in 2014, restructured how approved prescription drug labels present this kind of information, requiring a narrative summary of any available human and animal data, a risk summary, and clinical considerations for use in pregnancy and lactation, replacing the older A/B/C/D/X letter category system that many clinicians found oversimplified [1]. The existence of this detailed regulatory framework for approved drugs highlights, by contrast, what is missing for research peptides: there is no equivalent labeling, no equivalent risk summary, and no regulatory body compiling or requiring this data for compounds sold as "research use only."

Mechanistically, several categories of compounds commonly discussed in this space plausibly affect pregnancy through pathways studied in other contexts. Compounds that raise IGF-1 or otherwise affect growth signaling touch a pathway known to influence fetal growth. Compounds that promote angiogenesis (new blood vessel formation) intersect with a process that early embryonic and placental development is highly dependent on and sensitive to disruption. GLP-1 receptor agonists affect appetite, gastric emptying, and nutrient partitioning, pathways relevant to maternal weight and glucose regulation during pregnancy. These are Mechanistic Research observations, biologically reasonable concerns based on how these pathways behave elsewhere in development, not findings from studies of pregnant people using these specific peptides, because those studies do not exist.

What clinical evidence does exist involves FDA-approved GLP-1 medications, and it points toward caution rather than reassurance. The Ozempic (semaglutide) prescribing label instructs that the drug should be discontinued in women at least two months before a planned pregnancy, citing semaglutide's long systemic clearance time (a half-life of about one week, meaning it can remain in circulation for roughly two months), and states that available data on semaglutide use in pregnant women are insufficient to establish a drug-associated risk, while animal reproduction studies have shown adverse developmental effects [2]. That is Moderate Human Evidence in the sense that it draws on regulatory review of real pregnancy exposure data even though that data is still described as insufficient to draw firm conclusions, and it reflects a licensed, closely studied compound; the implied caution for a similarly acting but entirely unstudied research peptide is at least as strong, and arguably stronger given the complete absence of any registry or review process.

Growth hormone secretagogues, a category of peptides intended to increase the body's own growth hormone and, in turn, IGF-1 output, illustrate why growth-signaling pathways specifically warrant caution during pregnancy. IGF-1 is a normal and necessary part of fetal growth regulation, produced and controlled by the fetus and placenta through their own tightly regulated signaling, and there is no established clinical basis for assuming that externally elevating a pregnant person's growth hormone or IGF-1 levels through an unstudied compound interacts safely with that already-regulated system; the concern is not that growth signaling is inherently dangerous in pregnancy, since it is essential to normal fetal development, but that introducing an unstudied external input into a finely regulated system carries a plausible risk of disrupting rather than supporting it.

Compounds affecting reproductive hormone pathways deserve separate mention for anyone trying to conceive, not only for those already pregnant. Some peptides act on the hypothalamic-pituitary-gonadal (HPG) axis, the hormonal signaling chain that governs ovulation, and others have documented or theoretical effects on uterine blood flow or the receptivity of the uterine lining to implantation. None of this has been studied in people actively trying to conceive using research peptides, but the underlying pathways are ones known elsewhere in reproductive medicine to matter for conception and early pregnancy, which is why caution in this context is generally framed as starting before a positive pregnancy test rather than after one, similar to how the Ozempic label's two-month discontinuation-before-conception guidance is timed around the drug's clearance rather than around a confirmed pregnancy [2].

Breastfeeding introduces a separate consideration: many small-molecule and peptide-like compounds can pass into breast milk to some degree, and a newborn's liver and kidney function, the organs responsible for clearing most drugs from the body, are immature relative to an adult's, meaning a dose that produces a negligible effect in an adult could represent a larger relative exposure for an infant. This is a general pharmacokinetic principle recognized across drug classes, not a peptide-specific finding, but it is the reason lactation labeling exists as its own separate section under the PLLR rather than being inferred from pregnancy data alone [1].

It is worth distinguishing this discussion from FDA-approved peptide medications that are sometimes prescribed during pregnancy under direct medical supervision, most notably insulin for gestational diabetes. Insulin is a peptide hormone with decades of use and monitoring in pregnant people specifically, prescribed and dosed by a clinician who knows the pregnancy status and adjusts accordingly. That situation, an approved, monitored, clinician-directed peptide medication with an established pregnancy safety record, is categorically different from a self-administered, unapproved research peptide with no equivalent safety record, and the existence of the former does not imply anything about the safety of the latter.

The placenta itself is worth briefly explaining, because it is sometimes assumed to be a more complete barrier than it actually is. The placenta functions as a selective filter rather than an impermeable wall: it actively transports some substances, allows others to cross by simple diffusion based on size and solubility, and blocks relatively few compounds entirely. Peptides, being relatively small molecules, are not reliably excluded by placental transfer in the way this framing sometimes assumes, which is part of why regulatory agencies default to caution for any compound without specific pregnancy safety data rather than assuming a lack of data means a lack of exposure to the fetus.

The clearest limitation here is one of absence rather than conflict: there is essentially no human outcome data, positive or negative, for research peptides used during pregnancy or lactation, and no realistic path to generating that data ethically, since controlled trials intentionally exposing pregnant people to unapproved compounds are not conducted. That means the honest answer to "is this specific peptide safe during pregnancy" is that it has not been studied, not that it has been studied and found low-risk. Absence of evidence of harm is not evidence of absence of harm in this context, and clinical caution in analogous, better-studied compounds points the same direction as the mechanistic concerns above.

In practical terms, guidance around medication use in pregnancy generally centers on discussing any exposure, planned or already occurring, with an obstetric provider rather than making the determination independently, which is consistent with CDC guidance encouraging pregnant people to talk with their healthcare providers about any medicine use and to report exposures through established channels such as pregnancy registries or the FDA's MedWatch program [3]. Someone who is trying to conceive, or who discovers a pregnancy after already using a research peptide, is describing a situation for a clinician to evaluate, not one to resolve through self-assessment; a treating obstetric provider can review the specific compound, timing, and dose in the context of that pregnancy in a way this article cannot. This article explains why safety data for research peptides in pregnancy and lactation does not exist and what that absence implies; it is not a substitute for discussing any specific exposure with an obstetric or pediatric clinician.